A Phase 4 interventional study of 0.5 µg/kg remifentanil and 1.0 µg/kg remifentanil in Tachycardia, sponsored by Centre Hospitalier Universitaire de Nīmes. Completed at 2 sites in France. Open to participants aged 65 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-11-17.
Sponsored by Centre Hospitalier Universitaire de Nīmes · Phase 4, Interventional, and Treatment
The primary objective is to determine whether, during a rapid sequence intubation by etomidate, and succinylcholine Sellick maneuver, the administration of remifentanil at 2 different dosages (0.5 and 1.0 microgram per kg body weight), reduces potentially dangerous reactional tachycardia.
623 studies on the registry are indexed under Tachycardia; 81 are open to participants now.
This study's enrollment of 75 is above the median of 64 across 379 interventional studies indexed under Tachycardia.
Browse Tachycardia studies →Centre Hospitalier Universitaire de Nīmes is the lead sponsor of 587 studies on the registry; 96 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Induction anesthesia includes 0.5 µg/kg remifentanil in addition to classic induction anesthesia protocol.
Drug: 0.5 µg/kg remifentanil
Induction anesthesia includes 1.0 µg/kg remifentanil in addition to the classic induction protocol.
Drug: 1.0 µg/kg remifentanil
An equivalent volume (1 ml for 10 kg of weight) of isotonic 0.9% NaCl is injected in addition to the classic anesthesia induction protocol
Drug: NaCl
0.5 µg/kg remifentanil is used during induction in addition to the classic induction protocol
1.0 µg/kg remifentanil is added to the classic induction anesthesia protocol
an equivalent volume (1 ml for 10 kg of weight) of 0.9% isotonic NaCl is injected in addition to the classic anesthesia induction protocol
Cardiac frequency (beats per minute)
Patient cardiac frequency (beats per minute) at the time of induction
Time frame: 15 minutes
Plan to share: Yes — Data available upon request.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Nīmes